This site is part of the Siconnects Division of Sciinov Group

This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

Registration
Event
Hybrid Event

Accelerate Ideas, Partnerships and Opportunities

Book your SLOT NOW
  • Start 9:00am - 6:00pm
  • Dubai, UAE
 

About Conference

Sciinov Group is proud to announce the Oligonucleotide Therapeutics and Delivery Conference on February 03-04, 2025, in Dubai, UAE. This year's OTDC 2025 annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery, and targeting and optimizing delivery techniques for oligonucleotide-based therapies in the hope of continuing to drive forward the field of oligonucleotide...

Readmore

Author's Login
Abstract Tracking Tool

ask & questions

answer

We are always looking for new industry leaders to join our speaker faculty to deliver presentations, lead panel discussions and moderate sessions or roundtables. 
If you are interested in being considered as a speaker, submit your proposal/abstract Online

answer

We let speakers propose the topic they want to talk about. This process allows speakers to propose sessions that speak from their expertise and passion.
Speaker can choose the topic of your choice in related to the conference subject or any of their recent research work to present at our conference.
For details of scientific sessions covered please visit [not limited to, you can propose]  

 

answer

Please visit the page here

answer

Yes, as our conference is scheduled in Hybrid Mode, you can present and listen to full program virtually connecting via ZOOM live stream


Recent Updates

9 MAR
2023

Ansa Biotechnologies Announces Successful de novo Synthesis of World’s Longest Oligonucleotide at 1005 Bases

Ansa will be initiating an Early Access Program for clonal synthetic genes in April 2023Readmore

Feb 22
2022

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

Secarna’s LNAplusTM antisense oligonucleotides (ASOs) combined with Denali’s Oligonucleotide Transport Vehicle (OTV) technology provide potential for novel therapies in the area of difficult-to-treat central nervous system (CNS) diseasesReadmore

Feb 22
2022

Ansa Biotechnologies Achieves Breakthrough in DNA Synthesis

Ansa Biotechnologies is also launching an Early Access Program aimed at helping researchers obtain synthetic genes with sequences that were previously challenging to synthesizeReadmore

21 Aug
2023

Qalsody is an antisense oligonucleotide that targets SOD1 mRNA

FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosisReadmore


08:00-09:00

Registration

09:00-09:30

Opening Ceremony and Introduction

09:30-10:10

Keynote Session I

10:10-10:50

Keynote Session II

10:50-11:00

Refreshment Break

11:00-15:00

Break Out Session I

15:00-15:10

Refreshment Break

15:10-18:00

Break Out Session II

09:30-10:10

Keynote Session III

10:10-10:50

Keynote Session IV

10:50-11:00

Refreshment Break

11:00-15:00

Break Out Session III

15:00-15:10

Refreshment Break

15:10-18:00

Break Out Session IV

Get more information

make a booking now

Market Reports

Subscribe to our News & Updates